Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): RES19-T

            Therapeutic Area: Neurology Product Name: RES19-T

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Korys Investments

            Deal Size: $29.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing January 21, 2021

            Details:

            Proceeds from the fundraise will allow completion of proof-of-concept clinical trials for both the Alzheimer’s and the diabetes programs. A first-in-human trial of RES19-T for Alzheimer’s was initiated in 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): RES19-T

            Therapeutic Area: Neurology Product Name: RES19-T

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 03, 2020

            Details:

            RES19-T, a first-in-class small molecule, represents a novel approach to treat Alzheimer’s Disease (AD), aiming to address the disease at its root and restore cognition in patients by reducing the cellular damage associated with memory loss.